Last reviewed · How we verify
Treatment Period(JW0201)
JW0201 is a treatment for Treatment Period, but exact mechanism is unknown.
JW0201 is a treatment for Treatment Period, but exact mechanism is unknown. Used for Treatment Period.
At a glance
| Generic name | Treatment Period(JW0201) |
|---|---|
| Also known as | JW0201+C2022+C2203 |
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on JW0201's mechanism of action.
Approved indications
- Treatment Period
Common side effects
Key clinical trials
- To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus (PHASE3)
- To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM (PHASE3)
- To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers (PHASE1)
- To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment Period(JW0201) CI brief — competitive landscape report
- Treatment Period(JW0201) updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI